Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

References

• Cigarette smoking among adults and trends in smoking cessation – United States, 2008MMWR Morb Mortal Wkly Rep200958441227123219910909
   PubMedGoogle Scholar
• Annual smoking-attributable mortality, years of potential life lost, and economic costs – United States, 1995–1999MMWR Morb Mortal Wkly Rep2002511430030312002168
   PubMedGoogle Scholar
• MackayJEriksenMThe Tobacco AtlasGeneva, SwitzerlandWorld Health Organization2002
   Google Scholar
• Centers for Disease Control and PreventionThe health consequences of smoking: A report of the Surgeon General Available at: http://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm. Accessed Aug 19, 2010.
   Google Scholar
• MokdadAHMarksJSStroupDFGerberdingJLActual causes of death in the United States, 2000JAMA2004291101238124515010446
   PubMed Web of Science ®Google Scholar
• Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004MMWR Morb Mortal Wkly Rep200857451226122819008791
   PubMedGoogle Scholar
• US Department of Health and Human ServicesThe Health Benefits of Smoking Cessation: A report of the Surgeon GeneralAtlanta, GAUS Department of Health and Human Services1990
   Google Scholar
• MulcahyRInfluence of cigarette smoking on morbidity and mortality after myocardial infarctionBr Heart J19834954104156340707
   PubMedGoogle Scholar
• GodtfredsenNSLamTHHanselTTCOPD-related morbidity and mortality after smoking cessation: Status of the evidenceEur Respir J200832484485318827152
   PubMed Web of Science ®Google Scholar
• Cigarette smoking among adults – United States, 2000MMWR Morb Mortal Wkly Rep2002512964264512186222
   PubMedGoogle Scholar
• ZhuS-HMelcerTSunJRosbrookBPierceJPSmoking cessation with and without assistance: A population-based analysisAm J Prev Med200018430531110788733
   PubMed Web of Science ®Google Scholar
• HughesJRKeelyJNaudSShape of the relapse curve and long-term abstinence among untreated smokersAddiction2004991293814678060
   PubMed Web of Science ®Google Scholar
• FioreMCBaileyWCCohenSClinical Practice Guideline: Treating tobacco use and dependenceRockville, MDUS Department of Health and Human Services, Public Health Service2008
   Google Scholar
• HurtRDEbbertJOHaysJTMcFaddenDDTreating tobacco dependence in a medical settingCA Cancer J Clin200959531432619706827
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesThe Health Consequences of Smoking: Nicotine addiction. A report of the Surgeon GeneralWashington, DCUS Government Printing Office1988
   Google Scholar
• RollemaHCoeJWChambersLKHurstRSStahlSMWilliamsKERationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessationTrends Pharmacol Sci200728731632517573127
   PubMed Web of Science ®Google Scholar
• DaniJARoles of dopamine signaling in nicotine addictionMol Psychiatry20038325525612660795
   PubMed Web of Science ®Google Scholar
• ChangeuxJ-PNicotine addiction and nicotinic receptors: Lessons from genetically modified miceNat Rev Neurosci201011638940120485364
   PubMed Web of Science ®Google Scholar
• JensenAAFrølundBLiljeforsTKrogsgaard-LarsenPNeuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirationsJ Med Chem200548154705474516033252
   PubMed Web of Science ®Google Scholar
• WonnacottSSidhpuraNBalfourDJNicotine: From molecular mechanisms to behaviourCurr Opin Pharmacol200551535915661626
   PubMed Web of Science ®Google Scholar
• PapkeRLHeinemannSFPartial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunitMol Pharmacol19944511421498302273
   PubMed Web of Science ®Google Scholar
• EtterJ-FCytisine for smoking cessation: A literature review and a meta-analysisArch Intern Med2006166151553155916908787
   PubMedGoogle Scholar
• BarlowRBMcLeodLJSome studies on cytisine and its methylated derivativesBr J Pharmacol19693511611744387392
   PubMed Web of Science ®Google Scholar
• ReavillCWaltherBStolermanIPTestaBBehavioural and pharmacokinetic studies on nicotine, cytisine and lobelineNeuropharmacology19902976196242385332
   PubMed Web of Science ®Google Scholar
• CoeJWBrooksPRVetelinoMGVarenicline: An α4β2 nicotinic receptor partial agonist for smoking cessationJ Med Chem200548103474347715887955
   PubMed Web of Science ®Google Scholar
• MihalakKBCarrollFILuetjeCWVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptorsMol Pharmacol200670380180516766716
   PubMed Web of Science ®Google Scholar
• GonzalesDRennardSINidesMVarenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: A randomized controlled trialJAMA20062961475516820546
   PubMed Web of Science ®Google Scholar
• JorenbyDEHaysJTRigottiNAEfficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: A randomized controlled trialJAMA20062961566316820547
   PubMed Web of Science ®Google Scholar
• AubinHJBobakABrittonJRVarenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trialThorax200863871772418263663
   PubMed Web of Science ®Google Scholar
• CahillKSteadLFLancasterTNicotine receptor partial agonists for smoking cessationCochrane Database Syst Rev20091
   Google Scholar
• TonstadSTonnesenPHajekPEffect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trialJAMA20062961647116820548
   PubMed Web of Science ®Google Scholar
• HajekPTonnesenPArteagaCRussCTonstadSVarenicline in prevention of relapse to smoking: Effect of quit pattern on response to extended treatmentAddiction200910491597160219686530
   PubMed Web of Science ®Google Scholar
• WilliamsKEReevesKRBillingCBJrPenningtonAMGongJA double-blind study evaluating the long-term safety of varenicline for smoking cessationCurr Med Res Opin200723479380117407636
   PubMed Web of Science ®Google Scholar
• EbbertJOHaysJTHurtRDCombination pharmacotherapy for stopping smoking: What advantages does it offer?Drugs201070664365020394453
   PubMed Web of Science ®Google Scholar
• EbbertJOCroghanITSoodASchroederDRHaysJTHurtRDVarenicline and bupropion sustained-release combination therapy for smoking cessationNicotine Tob Res200911323423919246427
   PubMed Web of Science ®Google Scholar
• EbbertJOBurkeMVHaysJTHurtRDCombination treatment with varenicline and nicotine replacement therapyNicotine Tob Res200911557257619351781
   PubMed Web of Science ®Google Scholar
• SolbergLIParkerEDFoldesSSWalkerPFDisparities in tobacco cessation medication orders and fills among special populationsNicotine Tob Res201012214415120018945
   PubMed Web of Science ®Google Scholar
• HaysJTLeischowSJLawrenceDLeeTCAdherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherenceNicotine Tob Res201012657458120457644
   PubMed Web of Science ®Google Scholar
• SchaufflerHHMcMenaminSOlsonKBoyce-SmithGRideoutJAKamilJVariations in treatment benefits influence smoking cessation: Results of a randomised controlled trialTob Control200110217518011387540
   PubMed Web of Science ®Google Scholar
• CurrySJGrothausLCMcAfeeTPabiniakCUse and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organizationN Engl J Med1998339106736799725926
   PubMed Web of Science ®Google Scholar
• PetersenRGarrettJMMelvinCLHartmannKEMedicaid reimbursement for prenatal smoking intervention influences quitting and cessationTob Control2006151303416436401
   PubMed Web of Science ®Google Scholar
• HowardPKnightCBolerABakerCCost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: Application to a population of US adult smokersPharmacoeconomics200826649751118489200
   PubMed Web of Science ®Google Scholar
• LindenKJormanainenVLinnaMSintonenHWilsonKKotomakiTCost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokersCurr Med Res Opin201026354956020050814
   PubMed Web of Science ®Google Scholar
• AnnemansLNackaertsKBartschPPrignotJMarbaixSCost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: A BENESCO Markov cost-effectiveness analysisClin Drug Investig20092910655665
   PubMed Web of Science ®Google Scholar
• BolinKMorkACWillersSLindgrenBVarenicline as compared with bupropion in smoking-cessation therapy – cost-utility results for Sweden 2003Respir Med2008102569971018289839
   PubMed Web of Science ®Google Scholar
• HoogendoornMWelsingPRuttenvan MolkenMPCost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the NetherlandsCurr Med Res Opin2008241516118021492
   PubMed Web of Science ®Google Scholar
• KnightCHowardPBakerCLMartonJPThe cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: An extension and update to the BENESCO modelValue Health200913220921419912599
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationEarly communication about an ongoing safety review of varenicline (marketed as Chantix)11202010 Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070765.htm. Accessed May 25, 2010.
   Google Scholar
• US Food and Drug AdministrationVarenicline (marketed as Chantix) Information5162008 Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106540.htm. Accessed May 25, 2010.
   Google Scholar
• US Food and Drug AdministrationPublic Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban712009 Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm169988.htm. Accessed May 25, 2010.
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edition text revisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• TonstadSDaviesSFlammerMRussCHughesJPsychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysisDrug Saf201033428930120297861
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA: Boxed warning on serious mental health events to be required for Chantix and Zyban Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170100.htm. Accessed May 26, 2010.
   Google Scholar
• FaesselHMGibbsMAClarkDJRohrbacherKStolarMBursteinAHMultiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokersJ Clin Pharmacol200646121439144817101743
   PubMed Web of Science ®Google Scholar
• OnckenCGonzalesDNidesMEfficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessationArch Intern Med2006166151571157716908789
   PubMed Web of Science ®Google Scholar
• ObachRSReed-HagenAEKruegerSSMetabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitroDrug Metab Dispos200634112113016221753
   PubMed Web of Science ®Google Scholar
• Karam-HageMLamCBlalockJCinciripiniPIncreasing varenicline to 3 mgs/day improves abstinence rates: A preliminary efficacy report in cancer patientsPaper presented at: Society for Research on Nicotine and Tobacco Annual MeetingFeb 25, 2010Baltimore, MD
   Google Scholar
• Chantix® (varenicline) prescribing information. Available at: http://media.pfizer.com/files/products/uspi_chantix.pdf. Accessed Jun 3, 2010.
   Google Scholar